Biotech entity
Every one of those 1 sits in a single category, gene-therapy. NAFLD/NASH is most often covered alongside Dr. Eric Leire, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. NAFLD/NASH appears in 1 tracked Biotech story from August 8, 2026.
Last mentioned: Aug 8, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, gene-therapy. NAFLD/NASH is most often covered alongside Dr. Eric Leire, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. NAFLD/NASH appears in 1 tracked Biotech story from August 8, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NAFLD/NASH. Shared-story counts are live from our verified record — not editorial picks.
Genflow's centenarian-derived SIRT6 variant (N308K/A313S) continues to build IP protection, with a new US publication covering NAFLD/NASH and expansion into muscular diseases, underscoring the variant's pleiotropic potential in longevity and age-related conditions.
Source: bostonstar.com · dallassun.com
NAFLD/NASH is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
